A new study suggests GLP-1 receptor agonists and SGLT2 inhibitors may significantly reduce the risk of heart attacks and death in stroke survivors.

Dr. Reddy's Laboratories has launched BixiBat, a first-in-class drug containing Elobixibat, for treating chronic constipation in India, following approval from the CDSCO.

Luspatercept's approval offers an effective and well-tolerated first-line treatment for anemia in lower-risk myelodysplastic syndrome (MDS) patients without prior ESA use.

Precede Biosciences presented data at AACR LBx 2024 demonstrating its liquid biopsy platform's ability to accurately quantify tumor PSMA expression.

Data from Phase III open-label extension studies (PEDFIC 2 and ASSERT-EXT) demonstrate Bylvay's sustained efficacy in treating Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome (ALGS).

Long-term data from PEDFIC 2 shows odevixibat sustains reduction in pruritus and serum bile acid levels in PFIC patients over 72 weeks.

A Phase II study evaluated uPAR-PET/CT's efficacy in staging early breast cancer by targeting uPAR expression in tumors and lymph node metastases.

Eli Lilly's oral drug muvalaplin reduced lipoprotein(a) levels by up to 86% in adults with cardiovascular risk factors, meeting its primary endpoint.

Interius BioTherapeutics has received approval to begin a Phase 1 clinical trial for INT2104, a novel in vivo CAR therapy targeting B cell malignancies.

Nexcella's NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 100% overall response rate in AL amyloidosis patients relapsed or refractory to Darzalex-based regimens.

Error occurred while parsing the model response.

AiViva Biopharma has finished enrolling and dosing patients in a Phase 1 clinical trial of AIV007 for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Opna Bio has dosed the first subject in a Phase I clinical trial of OPN-6602, an EP300/CBP bromodomain inhibitor, for relapsed or refractory multiple myeloma.

EmVenio Research has launched clinical research sites within Prime Healthcare hospitals in Dallas and Atlanta to broaden patient access to trials.

Clearside Biomedical has completed the final participant visit in the ODYSSEY Phase 2b clinical trial evaluating CLS-AX for neovascular age-related macular degeneration (wet AMD).

The FDA granted Fast Track designation to Accutar Biotechnology's AC699 for treating ER+/HER2- breast cancer with ESR1 mutations after endocrine therapy.

The FDA has approved an expanded label for Grifols' Xembify, a 20% subcutaneous immunoglobulin, to include treatment-naïve patients with primary humoral immunodeficiencies (PI).